Skip to main content

Mariana Oncology — Deal History & Benchmarks

Total Deals
2
Across 1 therapeutic area
Total Deal Value
$2.2B
Cumulative transaction value
Most Active Year
2023
1 deal closed
Primary TA
Oncology
100% of deal activity

Market Analysis

Mariana Oncology has been involved in 2 transactions totaling $2.2B across Oncology. As a licensor (out-licensor), they have demonstrated an active acquisition strategy.

Key transactions include Novartis ($1.8B, 2024), AstraZeneca ($450M, 2023).

Their deal activity is concentrated in Oncology (100%) with Radiopharmaceutical assets representing their most common deal type.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How many deals has Mariana Oncology done?
Mariana Oncology has completed 2 verified transactions tracked in our database, spanning from 2023 to 2024. These deals have a combined value of $2.2B.
What is Mariana Oncology's typical deal structure?
Based on 2 deals, Mariana Oncology's transactions show a median upfront payment of $725M. Their most common deal type is acquisition, reflecting an active acquisition strategy.
What therapeutic areas does Mariana Oncology focus on?
Mariana Oncology focuses on Oncology, representing 100% of their tracked deals.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough